Alnylam Pharmaceuticals Inc (ALNY)vsJazz Pharmaceuticals PLC (JAZZ)
ALNY
Alnylam Pharmaceuticals Inc
$303.05
-0.19%
HEALTHCARE · Cap: $37.76B
JAZZ
Jazz Pharmaceuticals PLC
$238.57
-0.62%
HEALTHCARE · Cap: $14.48B
Smart Verdict
WallStSmart Research — data-driven comparison
Jazz Pharmaceuticals PLC generates 4% more annual revenue ($4.44B vs $4.29B). ALNY leads profitability with a 12.6% profit margin vs 0.7%. ALNY appears more attractively valued with a PEG of 0.48. ALNY earns a higher WallStSmart Score of 65/100 (B-).
ALNY
Strong Buy65
out of 100
Grade: B-
JAZZ
Buy56
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+86.4%
Fair Value
$2372.19
Current Price
$303.05
$2069.14 discount
Margin of Safety
+52.2%
Fair Value
$347.46
Current Price
$238.57
$108.89 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Every $100 of equity generates 54 in profit
Revenue surging 96.4% year-over-year
Strong operational efficiency at 23.0%
Growing faster than its price suggests
Strong operational efficiency at 23.5%
19.1% revenue growth
Areas to Watch
0.0% earnings growth
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 37.6x book value
3.2% earnings growth
ROE of 0.7% — below average capital efficiency
0.7% margin — thin
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on PEG Ratio, Return on Equity, Revenue Growth. Revenue growth of 96.4% demonstrates continued momentum. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : JAZZ
The strongest argument for JAZZ centers on PEG Ratio, Operating Margin, Revenue Growth. Revenue growth of 19.1% demonstrates continued momentum. PEG of 0.96 suggests the stock is reasonably priced for its growth.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, Debt/Equity, P/E Ratio. A P/E of 70.9x leaves little room for execution misses.
Bear Case : JAZZ
The primary concerns for JAZZ are EPS Growth, Return on Equity, Profit Margin. A P/E of 1921.3x leaves little room for execution misses. Thin 0.7% margins leave little buffer for downturns.
Key Dynamics to Monitor
JAZZ carries more volatility with a beta of 0.33 — expect wider price swings.
ALNY is growing revenue faster at 96.4% — sustainability is the question.
JAZZ generates stronger free cash flow (389M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ALNY scores higher overall (65/100 vs 56/100) and 96.4% revenue growth. JAZZ offers better value entry with a 52.2% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Jazz Pharmaceuticals PLC
HEALTHCARE · BIOTECHNOLOGY · USA
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and markets pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company is headquartered in Dublin, Ireland.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?